Industry News

IIROC Trading Resumption - HTL
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2016. The purpose of the call is to provide an update on Pfizer’ s results, as reflected in the company’ s Third Quarter 2016 Performance Report, to be issued that morning."/>
Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts
AmpliPhi Biosciences Corporation, a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced an update on the progress of its ongoing Phase 1 clinical trial for the treatment of S. aureus infections in patients suffering from chronic..."/>
AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients
Craneware, Inc., the healthcare market leader in automated value cycle solutions, today announced updates to its chargemaster management solutions, Chargemaster Toolkit ® Discovery Viewer and Chargemaster Toolkit ® Corporate Discovery Viewer. As provider organizations continue to transition to health information systems like Epic and Cerner, data that has traditionally resided in the chargemaster is being moved to detached, clinical..."/>
Craneware Debuts Data Visibility Updates to Award-Winning Chargemaster Solutions
bioMmune Technologies Inc., a biotechnology company that specializes in drug discovery and development, today announced the appointment of Dr."/>
BioMmune Appoints Thomas Gadek, PhD, to Board of Directors
Aethlon Medical, Inc., today announced changes to its corporate presentation schedule over the coming month. On September 6 th, the Company disclosed that its Chairman and CEO, Jim Joyce, would be presenting at the Aegis Capital 2016 Annual Growth Conference on Wednesday, September 21 st. Joyce will now participate in the Anti-Infectives RX Conference, taking place at Harvard Medical School in Boston, MA on Wednesday, September 21 st."/>
Aethlon Medical Updates Corporate Presentation Schedule
Great Basin Scientific, Inc., a molecular diagnostics company, announced today the U.S. and European commercial launch of its Staph ID/R Blood Culture Panel, the Company’ s first multiplex panel. This sample-to-result, automated panel benefits hospitals and laboratories by detecting, in about two hours, bloodstream infections caused by MRSA and other Staphylococcus species, enabling accurate, timely, and cost-effective diagnosis and treatment of..."/>
Great Basin Announces Commercial Launch of Staph ID/R Blood Culture Panel in U.S. and Europe
Ocera Therapeutics, Inc., a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2 nd Annual Healthcare Conference being held at the Sofitel New York in New York, New York on September 27, 2016. Ocera’ s presentation will take place in the Track 4 Orleans Room at 12:00 PM..."/>
Ocera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference
SCYNEXIS, Inc. today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.. A live webcast will be available on the investors section of the Company's website: A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the..."/>
SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference
Amgen today announced that the Phase 3 GLAGOV trial evaluating the effect of Repatha ® on coronary artery disease met its primary and secondary endpoints. The GLAGOV study is a large serial coronary intravascular imaging trial designed to test whether treatment with the proprotein convertase subtilisin/kexin type 9 inhibitor Repatha modifies atherosclerotic plaque build-up in the coronary arteries of patients already..."/>
Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 9:00 a.m. Eastern Time in New York City. A live webcast of ACADIA’ s presentation will be accessible on the company’ s website,..."/>
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
Venaxis ®, Inc., announced today that following its acquisition of BiOptix Diagnostics, Inc., that was announced on September 13, 2016, Venaxis has issued the following letter to its shareholders. The letter is posted on the company's website. On behalf of the Venaxis Board of Directors, I would like to take this opportunity to provide further information regarding our decision to acquire a controlling interest in BiOptix Diagnostics,..."/>
Venaxis Issues Shareholder Update
Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care, assisted living and urgent care companies, today announced that it has declared a quarterly cash dividend of $0.04 per share of Ensign common stock, payable on or before October 31, 2016, to shareholders of record as of September 30, 2016. Ensign has been a dividend-paying company since 2002.."/>
The Ensign Group Declares Quarterly Dividend of $0.04 Per Share
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced the appointment of Remi A. Menes as chief commercial officer, effective immediately. Mary Szela, Chief Executive Officer of Aegerion said,“ Remi brings extensive pre-launch and launch expertise and a proven ability to develop and lead commercial..."/>
Aegerion Pharmaceuticals Appoints Remi Menes as Chief Commercial Officer
Polaris Pharmaceuticals Adopts Medidata Payments
SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer, will present at the Annual Ladenburg Thalmann Healthcare Conference, being held on September 27, 2016 at The Sofitel, in New York City. Rigby will provide an overview and update on the..."/>
SteadyMed to Present at the Annual Ladenburg Thalmann 2016 Healthcare Conference
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today that it is conducting a pilot study with seqID inc using PositiveID’ s Firefly Dx polymerase chain reaction breadboard prototype pathogen detection system to detect genetically modified organisms for the agricultural market.. The goal of the pilot study with seqID is to demonstrate that Firefly Dx can successfully detect the 35 S..."/>
PositiveID and seqID Conduct Pilot Study Using Firefly Dx Prototype for GMO Detection for Agricultural Market
Laboratory Corporation of America ® Holdings, the world’ s leading healthcare diagnostics company, today announced that veteran biopharmaceutical executive John Ratliff will succeed Deborah Keller as CEO of Covance Drug Development, effective October 1. Ratliff will be a member of the LabCorp executive committee and will report to David P. King, chairman and CEO of LabCorp. This Smart News Release features multimedia."/>
LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology708 Articles
Consumer Discretionary588 Articles
Financials444 Articles
Industrials388 Articles
Health Care387 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at